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Purpose: Screening scale studies were performed with eight cultures for their ability to metabolize  
phenobarbital, an antiepileptic, sedative, hypnotic and substrate for CYP 2C9 and 2C19.   
Methods: The transformation of phenobarbital was confirmed and characterized by fermentation 
techniques, high performance liquid chromatography (HPLC), mass spectrometry (MS) and metabolism 
inhibition studies.  
Results: Among the different cultures screened, a fungus, Rhizopus stolonifer NCIM 880, transformed 
phenobarbital to its metabolite, the N-glucuronide of p- hydroxy phenobarbital. HPLC data show a 
solvent peak at 2.4 min, culture components peaks at 4.0 and 5.4 min, respectively, and phenobarbital 
peak at 10.3 min, for both controls and test samples, but only the sample of  Rhizopus stolonifer showed 
an additional peak at 3.1 min, indicating formation of a metabolite.   
Conclusion: Microbial metabolism of phenobarbital was similar to the metabolism of the drug in 
mammals. Therefore, Rhizopus stolonifer can be used as a suitable in vitro model to mimic CYP 2C9 
metabolism and to synthesize metabolites required for further pharmacological and toxicological studies.  
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INTRODUCTION 
 
An important factor in the evaluation of safety 
and efficacy of any drug is the knowledge 
about its metabolism. A better understanding 
of the metabolism of drug is essential to know 
about drug action, distribution, toxicity, 
excretion and storage in the body. Drug 
metabolism is a series of enzymatic 
biotransformation of chemical leading to 
formation of relatively polar substances, 
which are easily excreted. Drug metabolism 
studies are also important for studying 
induction/inhibition of metabolism of several 
drugs. Cytochrome P450 enzyme plays a 
major role in the metabolism of the drugs 
[1,2]. To underline the importance of CYP450 
and its isoforms, significant progress has 
been made in the use of in vitro methods to 
characterize the pharmacokinetics of 
potential drugs in man. This type of work 
requires selective substrates for each isoform 
of P450 system, to allow detailed metabolism 
experiments using microbes [3,4]. 
 
Drug metabolism studies have relied on the 
use of model systems to produce expected 
human metabolites of drugs. Traditionally, 
drug metabolism studies were conducted on 
small animal models, perfused organs, tissue 
culture, microsomal preparation [5,6]
 
in vitro 
enzyme systems and in vitro cell cultures. 
Microbial model was developed as one of the 
in vitro model to overcome the disadvantages 
of other models. Nowadays microbial model 
is used as a complementary tool to mimic 
mammalian metabolism by reducing the 
usage of animals in the drug development 
process. Microorganisms such as fungi, 
bacteria and yeast have been successfully 
used as in vitro models for the prediction of 
mammalian drug metabolism with successful 
applications [7-10]. 
  
Phenobarbital is mainly metabolized to p-
hydroxy phenobarbital and glucuronide 
conjugate of p-hydroxy phenobarbital in man, 
rats [11-13] and mice [14]. The present study 
was aimed at developing a microbial model to 
use as tool for the study of metabolism of 
drugs by CYP 2C9, as phenobarbital is a 
probe for CYP 2C9. The involvement of these 
enzymes in microbial metabolism would be 
confirmed by inhibition studies using CYP 






Cultures were obtained from National 
Chemical Laboratory (NCL), Pune and 
Microbial Type Culture Collection and Gene 
Bank (MTCC), Chandigarh, India. The 
cultures used in the present work were 
Streptomyces griseus (NCIM 2622), Nocardia 
hydrocarboxydans (NCIM 2386) Rhizopus 
stolonifer (NCIM 880), Cunninghamella 
blakesleeana (MTCC 3729), Cunninghamella 
elegans (NCIM 689), Cunninghamella 
echinulata (MTCC 4279), Aspergillus terreus 





Phenobarbital and fluoxetine were purchased 
from Sigma, Mumbai, India. Fenofibrate was 
a gift from Therdose Company, Hyderbad, 
India. All the reagents used in the analysis 
were of HPLC, including methanol and water 
(deionized and glass-distilled) which were 
obtained from SD Fine Chemicals Ltd, 
Mumbai, and ethylacetate from Merck, 
Mumbai, India.  Culture media components 
were purchased from Qualigens, and SD 




All the cultures were maintained on their 
respective agar slants at 4 °C and transferred 
every 6 months to maintain viability. The 
experiments were carried out using their 
respective growth media for the different 
microorganisms. The composition of the 
medium for bacteria was: beef extract,1 g; 
sodium chloride, 0.5 g; peptone, 1 g; distilled 
water, to 100 ml; final pH 7-7.5. For fungi, the 
composition was as follows: potato chips, 20 
g/100 ml (steamed for 30min.); dextrose, 2 g ; 
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yeast extract ,10 mg; distilled water, to 100 
ml; final pH 5.6. The medium for yeast 
was::malt extract, 0.3 g; glucose, 1 g; yeast 
extract, 0.3 g; peptone, 0.5 g; distilled water, 
to 100 ml; final pH 6.4 - 6.8  for yeast. These 
media were sterilized in individual 
Erlenmeyer flasks by autoclave at 121 °C at 





       
Fermentation for microbial metabolism was 
carried out in 250 ml Erlenmeyer flasks 
containing 50 ml medium. The culture flasks 
were incubated in a rotary shaker, operating 
at 120 rpm at 37 °C for 24 - 48 h. 
Fermentation was carried out according to 
standard protocol. The substrate (phenol-
barbital) was prepared by dissolving 20 mg of 
the drug in 10 ml of methanol, and 20 µg/ml 
was added to the culture medium of the 
selected organism and incubated in a shaker. 
For each biotransformation study, one 
sample and two controls were used. The 
study included the substrate control to which 
substrate was added and incubated without 
microorganism. Culture control consisted of 
fermentation blanks in which the 
microorganisms were grown under identical 
conditions without the substrate to test 
whether phenobarbital would be chemically 





The inhibition studies were carried out to 
confirm the involvement of specific CYP450 
isoenzyme in phenobarbital metabolism. One 
sample and four controls were used. These 
include a substrate control, inhibitor control 
and inhibitor and substrate control to check 
the interference of substrate, inhibitor alone 
and in combination with the media. Culture 
control consisted of fermentation blanks in 
which the microorganisms were grown under 
identical conditions without the substrate.   
     
The test was performed in two stages; in the 
first stage, drug control, culture control and 
inhibitor control were incubated in orbital 
shaker for 72 h. Inhibitor and substrate 
control and samples were incubated under 
the same conditions for 24 h by adding 20 
µg/ml of inhibitor. In second stage, i.e., after 
24 h of incubation 0.5 ml of drug solution was 
added to the inhibitor and substrate control 
and to the sample for a further 48-h 
incubation. The contents of the flask were 
extracted and analyzed by HPLC to 
determine the extent of inhibition of 
metabolism. 
   
The experiments were carried out in culture 
flasks (250 ml), each containing 50 ml of 
broth, and incubated in a rotary shaker 
operated under similar conditions. The 
substrate (phenobarbital), CYP 2C9 inhibitor, 
fenofibrate, and CYP 2C9 and 2C19 inhibitor, 
fluoxetine stock solutions, were prepared 





The incubated medium was heated on a 
water bath at 50 °C for 30 min and 
centrifuged at 3000 rpm for 10 min at 37 °C 
(Remi Instruments Pvt Ltd, Mumbai, India) A 
clear supernatant liquid was collected, 8ml of 
which was extracted with 5 ml of ethyl 
acetate [15].  The upper organic layer was 
separated and dried in vacuum dryer. During 
HPLC analysis, it was reconstituted with 0.5 
ml of mobile phase and centrifuged at 13000 
rpm for 10 min. Aliquots (25 µl each) were 
injected into the HPLC facility for analysis. 
Controls were also prepared similarly to 
provide suitable blanks.  
 
High pressure liquid chromatography 
(HPLC) 
 
High performance liquid chromatography 
(HPLC) analysis was carried out using a 
HPLC system (Waters, USA) which consisted 
of Waters 515 solvent delivery module, 
Waters  2489 UV- detector and a Wakosil II 
SC-18 rs-100 a. 5 µl, 4.6 x 250 mm stainless 
Kavitha et al 
Trop J Pharm Res, February2012;11 (1): 65 
steel column.  Sensitivity was set at 
0.001a.u.f.s. The mobile phase consisted of 
ammonium acetate buffer (0.025 M) of pH 5.5 
and methanol in a ratio of60:40 v/v and was 
used at a flow rate of 1 ml/min.  Elution was 
monitored using a UV-detector set at 220 nm. 
 
Mass spectrometry (MS) 
 
The metabolite found in the sample of 
Rhizopus stolonifer by HPLC analysis was 
collected from the elute for further analysis by 
mass spectrometry. MS/MS analysis was 
carried out using model API 3000, MS/MS 
operated with an ion trap mass spectrometer 
(IICT, Hyderabad) in positive electron spray 
ionization (ESI) source system. The interface 
was adjusted to the following conditions: ion 
mode, positive: spray voltage, 3.5 KV: 
capillary temperature, 325°C; and auxiliary 
gas (nitrogen), 40 Psi.  A mass spectrum was 
collected to obtain the protonated molecules 
(M+H) of drug and metabolite. MS/MS 
spectra were obtained by collision induced 





The results of inhibition studies are presented 
as the mean ± SD. The data were evaluated 
by paired Student’s ’t’-test using Graph Pad 
Prism, version 4.0 program and statistical 
significance was set at p < 0.001  
 
RESULTS      
 
The results of HPLC analysis of 
phenobarbital and its metabolite in different 
cultures are given in Table 1. The peaks at  
 
Table 1: HPLC data for phenobarbital  and its metabolite  obtained from a microbial culture extracts 
 
Retention time (min)   
 































































































































* Metabolite peak 
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the retention time of 2.4 min. represents 
solvent peak while the peaks at 4.0 and 5.4 
min represent culture components; the peak 
at 10.3 min represents phenobarbital. 
Rhizopus stolonifer showed an extra peak at 
3.1 min, as indicated in Fig 1.          
 
The mass spectrum of phenobarbital showed 
a molecular ion peak at m/z 231 while that  of 
the metabolite was at m/z 425 and fragment 
ion peaks occurred at 395, 379, 359, 351, 
343, 295, 269, 263, 177 and 174 (Fig 2).  The 
mass fragmentation pattern is shown  in Fig 
3, based on which the  metabolic pathway of 


























Fig 1: HPLC chromatogram of phenobarbital from 
culture extracts of Rhizopus stolonifer. Key: D = 
drug; M = metabolite; - = culture control; ■ = drug 
control; ▲= R. stolonifer sample 
 
 
Fig 2:  Mass spectrum of phenobarbital metabolite 
produced by Rhizopus stolonifer 
 
Table 2:  Data of metabolite formation and 
inhibition in inhibition studies  
 















* p < 0.001 compared to substrate (i.e., without 
inhibition) 
 
DISCUSSION                
 
Eight microorganisms were screened in the 
present study. The chromatograms of the 
culture controls did not show any peak for 
phenobarbital or its metabolite; however, the 
substrate control showed only the presence 
of phenobarbital. The samples of all cultures 
except the sample of Rhizopus stolonifer 
showed identical peaks in sample and 
controls which indicated that the organisms 
tested could not metabolize the drug, but 
interestingly an extra peak was detected in 
the sample of Rhizopus stolonifer, which 
represents the formation of phenobarbital 
metabolite, thus indicating the 
biotransformation of phenobarbital by 
Rhizopus stolonifer. 
 
The metabolite formed by Rhizopus stolonifer 
was isolated from elute of HPLC and its 
structure was identified by MS/MS analysis. 
The mass spectrum of phenobarbital 
exhibited a molecular ion peak at m/z 233 
(M+1). The molecular ion of m/z 425 (M+1) in 
mass spectrum of metabolite of 
phenobarbital represents the N-glucuronide 
of  p-hydroxy phenobarbital. Formation of the 
above metabolite was supported by fragment 
ion peaks at m/z 395, 379, 359, 351, 343, 
295, 269, 263, 177 and 174 (Fig 3). 
Phenobarbital is mainly metabolized to p- 
hydroxy phenobarbital and glucuronide 
conjugate of p- hydroxy phenobarbital in man 
and rats while N-glucuronide of p-hydroxy 
phenobarbital is found in mice [14].                
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Fig 3:  Mass fragmentation pattern of phenobarbital metabolite produced by Rhizopus stolonifer   
The inhibition are shown in Table 2., Fenofibrate inhibited 73.6 % of metabolite formation, with metabolite 
production decreasing from 38.17 to 10.05 % whereas fluoxetine inhibited 43.5 % of metabolite formation, 
decreasing formation of metabolite from 38.17 to 21.6 %. Percent metabolite formation or inhibition was 
calculated by taking the sum of drug and metabolite peak areas as 100%.  
 
The fungus, Rhizopus stolonifer, is of 
importance in medical mycology. It converted 
phenobarbital to N-glucuronide of p-hydroxy 
phenobarbital, indicating similarity with the 
metabolism of phenobarbital in mammals. 
The formation of the metabolite was 
confirmed by mass spectroscopy and 
inhibition studies. It has been documented 
that Rhizopus stolonifer metabolizes various 
drugs, including diclofenac [16], sclareol [17]
 
and α-agarofuran [18] to their respective 
metabolites similar to those formed in 
mammals. Based on the foregoing, the 
metabolic pathway of phenobarbital due to 
the action of Rhizopus stolonifer, is proposed 
as hydroxylation followed by glucuronidation.  
 
In the present study, a CYP 2C9 inhibitor, 
fenofibrate, and CYP 2C9 and 2C19 inhibitor, 
fluoxetine, were used, in the inhibition studies 
to confirm the involvement of a specific CYP 
enzyme in metabolite formation by Rhizopus 
stolonifer. Inhibition of metabolite formation 
was 73.6 % by fenofibrate and 43.5 % by 
fluoxetine. Thus, the two inhibitors not only 
demonstrated significant inhibition (p < 0.001) 
of phenobarbital metabolism by Rhizopus 
stolonifer but also showed that there was 
adifference in the capacity of the two 




The present study revealed the evidence for 
the functional role of the enzymes in 
Rhizopus stolonifer in the metabolism of 
phenobarbital in a manner similar similar to 
CYP 2C9 and 2C19. Inhibition by CYP 2C9 
inhibitor (fenofibrate) was significantly higher 
than by CYP 2C9 and 2C19 inhibitor 
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(fluoxetine), thus indicating the significant 
involvement of CYP 2C9 in the 
biotransformation of phenobarbital by 
Rhizopus stolonifer. Therefore, it can be 
concluded that Rhizopus stolonifer 
metabolizes phenobarbital to its N-
glucuronide of p-hydroxy phenobarbital by 
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